News
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...
1d
News-Medical.Net on MSNTirzepatide outperforms semaglutide for weight loss in people without diabetesA head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...
In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who ...
Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.
MÁLAGA, Spain — In the first head-to-head trial of its kind, tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity; Eli Lilly) produced significantly greater weight loss ...
A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...
The second episode of Pulse in Focus podcast is here. This time we are giving a guide to tirzepatide prescribing, and an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results